Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting

Interim data from Celator Pharmaceuticals' CPX-351 trial presented at the ASH meeting

Synta Pharmaceuticals announces study results of elesclomol

Synta Pharmaceuticals announces study results of elesclomol

New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

University of Texas M.D. Anderson Cancer Center and Stemline Therapeutics enter into research collaboration

University of Texas M.D. Anderson Cancer Center and Stemline Therapeutics enter into research collaboration

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

Two units of UCB reduce risk of leukemia from returning, shows new study

Two units of UCB reduce risk of leukemia from returning, shows new study

EpiCept announces third quarter 2009 financial results

EpiCept announces third quarter 2009 financial results

Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

Health Canada accepts for review the EpiCept’s New Drug Submission for Ceplene

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

Successful leukemia treatment with a radiolabeled antibody followed by stem cell transplant

Successful leukemia treatment with a radiolabeled antibody followed by stem cell transplant

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

New findings demonstrating pharmacoeconomic benefits of Ceplene released

New findings demonstrating pharmacoeconomic benefits of Ceplene released

Seattle Genetics reports its third-quarter financial results

Seattle Genetics reports its third-quarter financial results

Celgene announces fiscal 2009 third-quarter results

Celgene announces fiscal 2009 third-quarter results

NCCN Guidelines for Acute Myeloid Leukemia updated

NCCN Guidelines for Acute Myeloid Leukemia updated

Interim results from Phase 1 CAL-101 trial for chronic lymphocytic leukemia

Interim results from Phase 1 CAL-101 trial for chronic lymphocytic leukemia